Follow-up
A minimum of 8 weeks and up to 16 weeks of adherence monitoring was undertaken. At follow up, symptom control using TRACK, PACQLQ and offline FeNO were assessed. In addition, unscheduled healthcare visits (UHCVs) for acute attacks were recorded.